New approaches to COPD

European Respiratory Review

Volumn 14, Issue 94, 2005, Pages 2-11

  Barnes, P J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Adhesion molecule; Anti inflammatory; Chemokine; Cytokine; Phosphodiesterase 4; Tumour necrosis factor

Indexed keywords

ACETYLCYSTEINE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CELL ADHESION MOLECULE; CHEMOKINE; CILOMILAST; CORTICOSTEROID; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETANERCEPT; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLIXIMAB; INTERLEUKIN 10; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; MATRIX METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE SYNTHASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE IV INHIBITOR; RESVERATROL; RETINOID; ROFLUMILAST; SELENIUM; SERINE PROTEINASE; SUPEROXIDE DISMUTASE; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; DRUG BIOAVAILABILITY; EMPHYSEMA; FIBROSIS; HUMAN; INFLAMMATORY CELL; LUNG FUNCTION; LUNG PARENCHYMA; MUCUS SECRETION; NONHUMAN; OXIDATIVE STRESS; REVIEW; SMOKING CESSATION; SYSTEMATIC REVIEW;

EID: 24644472013     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09058180.05.00009401     Document Type: Review

References (101)

1. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998; 4: 1241-1243.
2. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003; 22: 672-688.
3. Barnes PJ. New concepts in COPD. Ann Rev Med 2003; 54: 113-129.
4. Barnes PJ. New treatments for COPD. Nature Rev Drug Disc 2002; 1: 437-445.
5. Barnes PJ. Chronic obstructive pulmonary disease. New Engl J Med 2000; 343: 269-280.
6. Fabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167: 418-424.
7. Wright JL, Churg A. Animal models of cigarette smoke-induced COPD. Chest 2002; 122: 301S-306S.
8. Tashkin DP, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo controlled, randomised trial. Lancet 2001; 357: 1571-1575.
9. B Dani JA. Roles of dopamine signaling in nicotine addiction. Mol Psychiatry 2003; 8: 255-256.
10. Kantak KM. Vaccines against drugs of abuse: a viable treatment option? Drugs 2003; 63: 341-352.
11. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategy for the diagnosis, management of chronic obstructive pulmonary disease. NHLBI/WHO Workshop Report 2003. www.goldcopd.com/workshop/ index.html. Date accessed: 1 October 2004.
12. Hansel TT, Barnes PJ. Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. Drugs Today 2002; 38: 585-600.
13. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19: 209-216.
14. Rutgers SR, Postma DS, ten Hacken NH, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000; 55: 12-18.
15. Barnes PJ. Cytokine modulators as novel therapies for airway disease. Eur Respir J, 2001; Suppl. 34, 67s-77s.
16. Highland KB, Strange C, Heffner JE. Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med 2003; 138: 969-973.
17. Culpitt SV, Rogers DF, Shah P, et al. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167: 24-31.
18. Ito K, Lim S, Caramori G, Chung KF, Barnes PJ, Adcock IM. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression and inhibits glucocorticoid actions in alveolar macrophages. FASEB J 2001; 15: 1100-1102.
19. Barnes PJ, Ito K, Adcock IM. A mechanism of corticosteroid resistance in COPD: inactivation of histone deacetylase. Lancet 2004; 363: 731-733.
20. Ito K, Lim S, Caramori G, et al. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 2002; 99: 8921-8926.
21. Barnes PJ. Theophylline: new perspectives on an old drug. Am J Respir Crit Care Med 2003; 167: 813-818.
22. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81.
23. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456.
24. Montuschi P, Collins JV, Ciabattoni G, et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000; 162: 1175-1177.
25. Paredi P, Kharitonov SA, Leak D, Ward S, Cramer D, Barnes PJ. Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 369-373.
26. MacNee W. Oxidants/antioxidants and COPD. Chest 2000; 117: Suppl. 1, 303S-317S.
27. Poole PJ, Black PN. Preventing exacerbations of chronic bronchitis and COPD: therapeutic potential of mucolytic agents. Am J Respir Med 2003; 2: 367-370.
28. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev 2001; 53: 135-159.
29. Chang LY, Subramaniam M, Yoder BA, et al. A catalytic antioxidant attenuates alveolar structural remodeling in bronchopulmonary dysplasia. Am J Respir Crit Care Med 2003; 167: 57-64.
30. Culpitt SV, Rogers DF, Fenwick PS, et al. Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax 2003; 58: 942-946.
31. Donnelly LE, Newton R, Kennedy GE, et al. Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am J Physiol Lung Cell Mol Physiol 2004; 287: L774-L783.
32. Ichinose M, Sugiura H, Yamagata S, Koarai A, Shirato K. Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways. Am J Resp Crit Care Med 2000; 160: 701-706.
33. Hansel TT, Kharitonov SA, Donnelly LE, et al. A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. FASEB J 2003; 17: 1298-1300.
34. Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med 1999; 160: 893-898.
35. Montuschi P, Kharitonov SA, Ciabattoni G, Barnes PJ. Exhaled leukotrienes and prostaglandins in COPD. Thorax 2003; 58: 585-588.
36. Yokomizo T, Kato K, Terawaki K, Izumi T, Shimizu T. A second leukotriene B4 receptor BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med 2000; 192: 421-432.
37. Silbaugh SA, Stengel PW, Cockerham SL, et al. Pharmacologic actions of the second generation leukotriene B4 receptor antagonist LY29311: in vivo pulmonary studies. Naunyn Schmiedebergs Arch Pharmacol 2000; 361: 397-404.
38. Crooks SW, Bayley DL, Hill SL, Stockley RA. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J 2000; 15: 274-280.
39. Beeh KM, Kornmann O, Buhl R, Culpitt SV, Giembycz MA, Barnes PJ. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest 2003; 123: 1240-1247.
40. Gompertz S, Stockley RA. A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD. Chest 2002; 122: 289-294.
41. Panina-Bordignon P, D'Ambrosio D. Chemokines and their receptors in asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med 2003; 9: 104-110.
42. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153: 530-534.
43. Traves SL, Culpitt S, Russell REK, Barnes PJ, Donnelly LE. Elevated levels of the chemokines GRO-α and MCP-1 in sputum samples from COPD patients. Thorax 2002; 57: 590-595.
44. Hay DWP, Sarau HM. Interleukin-8 receptor antagonists in pulmonary diseases. Curr Opin Pharmacol 2001; 1: 242-247.
45. de Boer WI, Sont JK, van Schadewijk A, Stolk J, van Krieken JH, Hiemstra PS. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol 2000; 190: 619-626.
46. Saetta M, Mariani M, Panina-Bordignon P, et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 165: 1404-1409.
47. Vernooy JH, Kucukaycan M, Jacobs JA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002; 166: 1218-1224.
48. de Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM. Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med 1996; 153: 633-637.
49. Reimold AM. TNFα as therapeutic target: new drugs, more applications. Curr Drug Targets Inflamm Allergy 2002; 1: 377-392.
50. Davenpeck KL, Berens KL, Dixon RA, Dupre B, Bochner BS. Inhibition of adhesion of human neutrophils and eosinophils to P-selectin by the sialyl Lewis antagonist TBC1269: preferential activity against neutrophil adhesion in vitro. J Allergy Clin Immunol 2000; 105: 769-775.
51. Noguera A, Busquets X, Sauleda J, Villaverde JM, MacNee W, Agusti AG. Expression of adhesion molecules and G proteins in circulating neutrophils in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 1664-1668.
52. Takanashi S, Hasegawa Y, Kanehira Y, et al. Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Eur Respir J 1999; 14: 309-314.
53. Sturton G, Fitzgerald M. Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest 2002; 121: 192S-196S.
54. Compton CH, Gubb J, Nieman R, et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 2001; 358: 265-270.
55. Gamble E, Grootendorst DC, Brightling CE, et al. Anti-inflammatory effects of the phosphodiesterase 4 inhibitor cilomilast (Ariflo) in COPD. Am J Respir Crit Care Med 2003; 168: 976-982.
56. Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 2003; 370: 1-18.
57. Lamontagne S, Meadows E, Luk P, et al. Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey. Brain Res 2001; 920: 84-96.
58. Robichaud A, Stamatiou PB, Jin SL, et al. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 2002; 110: 1045-1052.
59. Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci U S A 2002; 99: 7628-7633.
60. Kuss H, Hoefgen N, Johanssen S, Kronbach T, Rundfeldt C. In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5- hydroxy-indole-3-yl]-glyo xylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration. J Pharmacol Exp Ther 2003; 307: 373-385.
61. Di Stefano A, Caramori G, Capelli A, et al. Increased expression of NF-kB in bronchial biopsies from smokers and patients with COPD. Eur Resp J 2002; 20: 556-563.
62. Caramori G, Romagnoli M, Casolari P, et al. Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. Thorax 2003; 58: 348-351.
63. Delhase M, Li N, Karin M. Kinase regulation in inflammatory response. Nature 2000; 406: 367-368.
64. Castro AC, Dang LC, Soucy F, et al. Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett 2003; 13: 2419-2422.
65. Nasuhara Y, Adcock IM, Catley M, Barnes PJ, Newton R. Differential IKK activation and IkBa degradation by interleukin-1b and tumor necrosis factor-a in human U937 monocytic cells: evidence for additional regulatory steps in kB-dependent transcription. J Biol Chem 1999; 274: 19965-19972.
66. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298: 1911-1912.
67. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003; 2: 717-726.
68. Underwood DC, Osborn RR, Bochnowicz S, et al. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol 2000; 279: L895-L902.
69. Sasaki T, Irie-Sasaki J, Jones RG, et al. Function of P13Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 2000; 287: 1040-1046.
70. Ward S, Sotsios Y, Dowden J, Bruce I, Finan P. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem Biol 2003; 10: 207-213.
71. Patel HJ, Belvisi MG, Bishop-Bailey D, Yacoub MH, Mitchell JA. Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy. J Immunol 2003; 170: 2663-2669.
72. Harris SG, Phipps RP. Induction of apoptosis in mouse T cells upon peroxisome proliferator-activated receptor gamma (PPAR-g) binding. Adv Exp Med Biol 2002; 507: 421-425.
73. Vestbo J. Epidemiological studies in mucus hypersecretion. Novartis Found Symp 2002; 248: 3-12.
74. Barnes PJ. Current and future therapies for airway mucus hypersecretion. Novartis Found Symp 2002; 248: 237-249.
75. Nadel JA, Burgel PR. The role of epidermal growth factor in mucus production. Curr Opin Pharmacol 2001; 1: 254-258.
76. Zhou Y, Shapiro M, Dong Q, et al. A calcium-activated chloride channel blocker inhibits goblet cell metaplasia and mucus overproduction. Novartis Found Symp 2002; 248: 150-165.
77. Rogers DF. Pharmacological regulation of the neuronal control of airway mucus secretion. Curr Opin Pharmacol 2002; 2: 249-255.
78. de Boer WI, van Schadewrjk A, Sont JK, et al. Transforming growth factor beta1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 1951-1957.
79. Takizawa H, Tanaka M, Takami K, et al. Increased expression of transforming growth factor-β1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 2001; 163: 1476-1483.
80. Dallas SL, Rosser JL, Mundy GR, Bonewald LF. Proteolysis of latent transforming growth factor-β (TGF-β)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-b from bone matrix. J Biol Chem 2002; 277: 21352-21360.
81. Mak JC, Rousell J, Haddad EB, Barnes PJ. Transforming growth factor-b1 inhibits β2-adrenoceptor gene transcription. Naunyn Schmiedebergs Arch Pharmacol 2000; 362: 520-525.
82. Ishikawa T, Kume H, Kondo M, Ito Y, Yamaki K, Shimokata K. Inhibitory effects of interferon-gamma on the heterologous desensitization of beta-adrenoceptors by transforming growth factor-β1 in tracheal smooth muscle. Clin Exp Allergy 2003; 33: 808-815.
83. DaCosta BS, Major C, Laping NJ, Roberts AB. SB-505124 is a selective inhibitor of transforming growth factor-β type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2004; 65: 744-752.
84. Miotto D, Hollenberg MD, Bunnett NW, et al. Expression of protease activated receptor-2 (PAR-2) in central airways of smokers and non-smokers. Thorax 2002; 57: 146-151.
85. Vliagoftis H, Schwingshackl A, Milne CD, et al. Proteinase-activated receptor-2-mediated matrix metalloproteinase-9 release from airway epithelial cells. J Allergy Clin Immunol 2000; 106: 537-545.
86. Frungieri MB, Weidinger S, Meineke V, Kohn FM, Mayerhofer A. Proliferative action of mast-cell tryptase is mediated by PAR2, COX2, prostaglandins, and PPARy: Possible relevance to human fibrotic disorders. Proc Natl Acad Sci USA 2002; 99: 15072-15077.
87. Shapiro SD, Senior RM. Matrix metalloproteinases. Matrix degradation and more. Am J Respir Cell Mol Biol 1999; 20: 1100-1102.
88. Luisetti M, Travis J. Bioengineering: alpha 1-proteinase inhibitor site-specific mutagenesis. The prospect for improving the inhibitor. Chest 1996; 110: 278S-283S.
89. Stecenko AA, Brigham KL. Gene therapy progress and prospects: alpha-1 antitrypsin. Gene Ther 2003; 10: 95-99.
90. Luisetti M, Sturani C, Sella D, et al. MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial. Eur Respir J 1996; 9: 1482-1486.
91. Leung-Toung R, Li W, Tam TF, Karimian K. Thiol-dependent enzymes and their inhibitors: a review. Curr Med Chem 2002; 9: 979-1002.
92. Belvisi MG, Bottomley KM. The role of matrix metallo-proteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs? Inflamm Res 2003; 52: 95-100.
93. Russell RE, Culpitt SV, DeMatos C, et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002; 26: 602-609.
94. Massaro G, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nature Med 1997; 3: 675-677.
95. Belloni PN, Garvin L, Mao CP, Bailey-Healy I, Leaffer D. Effects of all-trans-retinoic acid in promoting alveolar repair. Chest 2000; 117: 235S-241S.
96. Lucey EC, Goldstein RH, Breuer R, Rexer BN, Ong DE, Snider GL. Retinoic acid does not affect alveolar septation in adult FVB mice with elastase-induced emphysema. Respiration 2003; 70: 200-205.
97. Mao JT, Goldin JG, Dermand J, et al. A pilot study of all-trans-retinoic acid for the treatment of human emphysema. Am J Respir Crit Care Med 2002; 165: 718-723.
98. Otto WR. Lung epithelial stem cells. J Pathol 2002; 197: 527-535.
99. Sandford AJ, Silverman EK. Chronic obstructive pulmonary disease. 1: Susceptibility factors for COPD the genotype-environment interaction. Thorax 2002; 57: 736-741.
100. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1693-1772.
101. Dowson LJ, Guest PJ, Stockley RA. Longitudinal changes in physiological, radiological, and health status measurements in α1-antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med 2001; 164: 1805-1809.